Shareholders' Deficit (Tables)

6 Months Ended

12 Months Ended

May 31, 2013

Nov. 30, 2012

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense by type of award for the second quarter and first half of fiscal 2013 and 2012 was as follows:

	Three months ended May 31,				Six months ended May 31,
	2013		2012		2013		2012
	(In millions)
Stock appreciation rights	$	2.2	$	0.1	$	4.7	$	0.4
Stock options		—		0.3		—		0.4
Restricted stock, service based		0.7		0.7		1.2		1.1
Restricted stock, performance based		0.2		0.2		0.4		0.3
Total stock-based compensation expense	$	3.1	$	1.3	$	6.3	$	2.2

Total stock-based compensation expense by type of award was as follows:

	Year Ended
	2012		2011		2010
	(In millions)
Stock appreciation rights (“SARS”)	$	2.7	$	0.4	$	(0.9	)
Stock options		0.8		0.9		0.2
Restricted stock, service-based		2.2		1.7		1.0
Restricted stock, performance-based		0.8		0.7		0.1
Total stock-based compensation expense	$	6.5	$	3.7	$	0.4

Summary of Stock Appreciation Rights

A summary of the status of the Company’s SARS as of November 30, 2012 and changes during fiscal 2012 is presented below:

	SARS (In thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value (In millions)
Outstanding at November 30, 2011		1,438		$	10.75
Granted		99			6.82
Cancelled		(8	)		14.88
Outstanding at November 30, 2012		1,529		$	10.47		4.4	$	2.9
Exercisable at November 30, 2012		1,402		$	10.90		4.3	$	2.4
Expected to vest at November 30, 2012		122		$	5.70		5.9	$	0.4

Schedule of Stock Options Activity

A summary of the status of the Company’s stock options as of November 30, 2012 and changes during fiscal 2012 is presented below:

	Stock Options (In thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Intrinsic Value (In millions)
Outstanding at November 30, 2011		1,234		$	7.17
Granted		9			6.00
Exercised		(184	)		7.30
Cancelled		(210	)		12.22
Outstanding at November 30, 2012		849		$	5.87		4.6	$	2.9
Exercisable at November 30, 2012		360		$	6.67		4.0	$	1.0
Expected to vest at November 30, 2012		446		$	5.55		4.9	$	1.6

Summary of Range of Exercise Prices and Weighted-Average Exercise Prices for Options Outstanding

The following table summarizes the range of exercise prices and weighted-average exercise prices for options outstanding as of November 30, 2012 under the Company’s stock option plans:

		Outstanding
Year Granted	Range of Exercise Prices	Stock Options Outstanding (In thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (years)
2003	$7.73 – $9.29		103	$	8.46		0.4
2004	$10.92		28	$	10.92		1.2
2009	$4.54		154	$	4.54		6.6
2010	$4.91 – $7.14		456	$	6.82		5.6
2011	$6.01		100	$	6.01		5.3
2012	$6.00		8	$	6.00		9.2
			849

Restricted shares, service based [Member]

Summary of Restricted Stock Units

The following is summary of the status of the Company’s service-based restricted stock as of November 30, 2012 and changes during fiscal 2012:

	Service Based Restricted Stock (In thousands)			Weighted Average Grant Date Fair Value
Outstanding at November 30, 2011		473		$	5.80
Granted		384			7.05
Vested		(213	)		6.69
Canceled		(6	)		5.11
Outstanding at November 30, 2012		638		$	6.41
Expected to vest at November 30, 2012		631		$	6.41

Performance-based restricted stock [Member]

Summary of Restricted Stock Units

The following is a summary of the status of the Company’s performance-based restricted stock as of November 30, 2012 and changes during fiscal 2012:

	Performance Based Restricted Stock (In thousands)			Weighted Average Grant Date Fair Value
Outstanding at November 30, 2011		428		$	5.37
Granted		333			6.87
Vested		(126	)		6.00
Cancelled		(5	)		4.91
Outstanding at November 30, 2012		630		$	6.33
Expected to vest at November 30, 2012		502		$	6.42

Employee Stock Option [Member]

Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options

The fair value of stock options was estimated using a Black-Scholes Model with the following weighted average assumptions:

	Year Ended
	2012			2011			2010
Expected life (in years)		7.0			7.0			7.0
Volatility		57.47	%		57.19	%		55.43	%
Risk-free interest rate		1.54	%		2.53	%		2.44	%
Dividend yield		0.00	%		0.00	%		0.00	%

Stock Appreciation Rights [Member]

Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options

The fair value of SARS was estimated using a Black-Scholes Model with the following weighted average assumptions:

	Year Ended
	2012			2011			2010
Expected life (in years)		3.7			4.4			5.1
Volatility		55.47	%		62.60	%		66.53	%
Risk-free interest rate		0.51	%		0.91	%		1.56	%
Dividend yield		0.00	%		0.00	%		0.00	%